Erratum: Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies (Modern Pathology (2015) DOI: 10.1038/modpathol.2015.66);Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies

Modern Pathology

Volumn 28, Issue 8, 2015, Pages 1014-1022

  Cameron Yin, C ^a   Peng, Jie ^a   Li, Yu ^a   Shamanna, Rashmi K ^a   Muzzafar, Tariq ^a   Dinardo, Courtney ^a   Khoury, Joseph D ^a   Li, Shaoying ^a   Jeffrey Medeiros, L ^a   Wang, Sa A ^a   Tang, Guilin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BONE MARROW; BONE MARROW TUMOR; BREAST CANCER; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHROMOSOME 20Q; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME DELETION 20Q; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CLONAL EVOLUTION; COLON CANCER; CONTROLLED STUDY; DRUG INDUCED CANCER; DRUG MEGADOSE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; KARYOTYPE; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; METAPHASE CHROMOSOME; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; THERAPY RELATED MYELODYSPLASTIC SYNDROME; THERAPY RELATED MYELOID NEOPLASM; WALDENSTROEM MACROGLOBULINEMIA; ADVERSE EFFECTS; BONE MARROW EXAMINATION; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; CHROMOSOME 20; CHROMOSOME ABERRATION; DRUG EFFECTS; FACTUAL DATABASE; GENETICS; KAPLAN MEIER METHOD; METAPHASE; MORTALITY; PATHOLOGY; RADIATION INDUCED NEOPLASM; RADIATION RESPONSE; RADIOTHERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SECOND CANCER; STEM CELL TRANSPLANTATION; TEXAS; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW EXAMINATION; CHEMORADIOTHERAPY; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CLONAL EVOLUTION; DATABASES, FACTUAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; METAPHASE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TEXAS; TIME FACTORS;

EID: 84938423043     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.76     Document Type: Erratum

References (31)

1. Brunning RD, Orazi A, Germing U et al. Myelodysplas-tic syndromes/neoplasms, overview. In: Swerdlow S, Campo E, Harris N et al. (eds) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Stylus Publishing, LLC: Sterling, VA, 2008, pp 88-93.
2. Bacher U, Schnittger S, Kern W et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 2009;88:1207-1213.
3. Heim S, Mitelman F. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 1992;70:1701-1709.
4. Bench AJ, Aldred MA, Humphray SJ et al. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics 1998;49:351-362.
5. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodys-plastic syndromes. Blood 2012;120:2454-2465.
6. Gupta R, Soupir CP, Johari V et al. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007;139:265-268.
7. Caramazza D, Begna KH, Gangat N et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011;25: 82-88.
8. Campbell LJ, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 1994;8:67-71.
9. Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010;115:453-474.
10. Braun T, de Botton S, Taksin AL et al. Characteristics and outcome of myelodysplastic syndromes(MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011;35:863-867.
11. Sashida G, Takaku TI, Shoji N et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma 2003;44:653-658.
12. Steensma DP, Dewald GW, Hodnefield JM et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res 2003;27: 235-242.
13. Vardiman J, Arber D, Brunning R et al. Therapy-related myeloid neoplasms. In: Swerdlow S, Campo E, Harris N et al. (eds). WHO Classification of Tumors of Hemato-poietic and Lymphoid Tissues. IARC: Lyon, 2008, pp 127-129.
14. Ok CY, Hasserjian RP, Fox PS et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromesand oligo-blastic acute myeloid leukemia. Leukemia 2014;28: 185-189.
15. Klimek VM. Recent advances in the management of therapy-related myelodysplastic syndromesand acute myeloid leukemia. Curr Opin Hematol 2013;20: 137-143.
16. Pedersen-Bjergaard J, Pedersen M, Roulston D et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodyspla-sia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-3552.
17. Kanagal-Shamanna R, Yin CC, Miranda RN et al. Therapy-related myeloid neoplasms with isolated del (20q): comparison with cases of de novo myelo-dysplastic syndrome with del(20q). Cancer Genet 2013;206:42-46.
18. Tang G, Wang SA, Lu V et al. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res 2014;38:896-900.
19. Shaffer L, McGowan-Jordan J, Schmid M. International system for human cytogenetic nomenclature (ISCN 2013) Recommendations of the International Standing Commitee on Human Cytogenetic Nomenclature. Basel: Karger. 2013;39-83.
20. Wang SA, Hutchinson L, Tang G et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013;88: 219-224.
21. Pan J, Wu C, Xue Y et al. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series. Cancer Genet 2014;207:51-56.
22. Mallo M, Luno E, Sanzo C et al. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res 2011;35:834-836.
23. Okada M, Suto Y, Hirai M et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet 2012;205: 18-24.
24. Wang PW, Iannantuoni K, Davis EM et al. Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 1998;21:75-81.
25. Nacheva E, Holloway T, Carter N et al. Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes. Cancer Genet Cytogenet 1995;80:87-94.
26. Bench AJ, Nacheva EP, Hood TL et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000;19: 3902-3913.
27. Huh J, Tiu RV, Gondek LP et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 2010;49:390-399.
28. Gurvich N, Perna F, Farina A et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci USA 2010;107:22552-22557.
29. Goswami RS, Liang CS, Bueso-Ramos CE et al. Isolated +15 in bone marrow: Disease-associated or a benign finding? Leuk Res 2015;39:72-76.
30. Basecke J, Podleschny M, Becker A et al. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol 2008;141:52-59.
31. Lopez de Mesa R, Sierrasesumaga L, Calasanz MJ et al. Nonclonal chromosomal aberrations induced by anti-tumoral regimens in childhood cancer: relationship with cancer-related genes and fragile sites. Cancer Genet Cytogenet 2000;121:78-85.